- Everyday Alpha
- Posts
- The $170B Revenue Machine the Market Is Undervaluing
The $170B Revenue Machine the Market Is Undervaluing
When an insider bets $7.2M of his own money, smart investors pay attention.
Elevance Health's CTO just wrote a personal check for $7.2 million to buy his own company's stock. The chairman followed with another $336,000 in the same week.
When the people who know a business best open their wallets at these levels, it is worth paying attention.
The Wealth Strategy (Sponsored)
His reported salary? $400,000 annually.
Yet the bigger number tells a different story: Up to $250,000 each month… from one channel.
It’s not property. It’s not stocks.
So what’s behind this kind of consistent income — and why is it catching attention right now?
Elevance Health
Date – Pre‑market
Ticker: ELV | Sector: Healthcare | Market Cap: $85.33B
30‑Second Take
Why now? When a company's own Chief Technology Officer writes a personal check for $7.2 million to buy his own stock, that's worth a second look.
And when the chairman, who has been on the board since 2004, follows him up in the same week with another $336,000 of his own money, it's time to dig in properly.
The insider buying at Elevance has clustered up in a big way over the last two weeks, with multiple officers and directors filing Form 4s. It's a rare signal, and a clean one.
The managed care sector has been through the wringer for months on Medicaid margin fears and utilization spikes, and ELV got dragged down with the rest of them. Now the people who know the business best are opening their own wallets at these levels.
If you're looking for a defensive name with a re-rating catalyst, ELV could well fit the bill.
Trade Setup
Time frame: Swing to medium-term (3 to 9 months)
Edge type: Insider cluster + mean reversion
Easy Trading (Sponsored)
Early adopters could have already multiplied their money year after year with this AI, based on the average winning trades it identifies – WITHOUT reading headlines, WITHOUT tracking interest rates, and WITHOUT the constant pressure most traders face.
Right now, you can test this AI yourself, completely free – no email, no credit card required.
Click here to learn more.
When you're building conviction in a new position, what matters most in your research process? |
Snapshot Table
Metric | Value | Current Stance |
|---|---|---|
Price | $393.44 | Middle of 52-week range |
52‑week range | $273.71 - $436.24 | Currently near upper third |
Market Cap | $82.89B | Large-cap defensive |
Beta | 0.68 | Low volatility vs market |
P/E Ratio | 16.65 | Moderate valuation |
Avg Daily Volume | 1.76M | Normal liquidity |
Next Catalyst | Q3 2026 earnings, expected late October | Key margin update |
Chart
1-Month Synopsis: ELV has climbed off the June lows and now trades in the upper half of its 52-week range. The move higher has picked up steam as insider purchases hit the wire, with volume rising on the up days.
That's the pattern you want to see.
The stock is still well off its 52-week high near $436, leaving roughly 14% upside just to get back to prior highs. Analyst targets point to more beyond that.
Bull Case
Core thesis: Insiders don't buy for fun. Options grants and RSUs are how executives typically accumulate stock in a large-cap healthcare name.
Writing a personal check for $7.2 million of your own money is a completely different animal. That's what the CTO just did.
The chairman, someone who has sat on this board since 2004 and knows every corner of the business, piled in with another $336,000. This isn't a token buy to look good in an SEC filing.
Catalysts: Managed care got treated like a broken sector through late 2025 and into early 2026. It isn't.
Elevance has around 47 million members, over $170 billion in annual revenue, and a Carelon services business that keeps compounding quarter after quarter.
Multiple insiders buying on the open market in the same window is a cluster signal. The stock sits in the middle of its 52-week range, not extended. Managed care as a group trades at a discount to its historical P/E multiple. And the Q3 print in late October is the next real catalyst.
Valuation upside: Even a modest multiple re-rate paired with reaffirmed 2026 guidance gets you back toward that prior high. If the market rotates out of stretched AI names and into defensive quality, ELV is exactly the kind of stock money hides in.
Technical tailwind: A low beta of 0.68 means less drawdown risk if the broader market wobbles. Volume is confirming the move higher, and the Form 4 filings keep coming.
Bear Case
The obvious risk is policy. Medicaid and Medicare Advantage rates are political footballs, and every election cycle brings fresh threats to reimbursement.
If utilization stays elevated or a new administration takes a harder line on MA payment rates, the whole sector re-prices lower. Elevance goes with it.
A few things could break the thesis. Q3 earnings showing medical loss ratios ticking higher instead of stabilizing. CMS finalizing an MA rate below expectations. A major state Medicaid contract getting repriced unfavorably. Or a broader market correction dragging defensives down alongside growth.
Insider buying is a strong signal. It isn't a guarantee. Executives can be wrong, and $7 million isn't life-changing money for a Fortune 500 CTO. Size this appropriately.
There's also value trap risk. Managed care has looked cheap for months, and yet it keeps getting cheaper. Set a stop and honor it if the thesis breaks.
Quick Checklist
✅ Thesis still valid after today's close
✅ Volume confirms move above key levels
✅ Insider filings continuing (check Form 4s weekly)
Deep‑Dive Links
That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!
Best Regards,
—Noah Zelvis
Everyday Alpha